P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808
Jonathan E. Kolitz(Memorial Sloan Kettering Cancer Center), Vera Hárs, Wendy Stock(University of Chicago), Stephen L. George(Duke University), Eva Hoke(Leukemia Research Foundation), Ravi Vij(Washington University in St. Louis), Maria R. Baer(University of Maryland, Baltimore), Guido Marcucci(City of Hope), Clara D. Bloomfield(North Shore University Hospital), Richard A. Larson(Urbana University), Steven L. Allen(Albert Einstein College of Medicine), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Thomas C. Shea(University of North Carolina at Chapel Hill), Bayard L. Powell(Atrium Health Wake Forest Baptist), Kati Maharry(Peter MacCallum Cancer Centre), James W. Vardiman(University of Chicago)
Cited by 129
Related Papers
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
|Blood|2016|10.2k
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k